Silencing gene expression to cure complex diseases

By October 26, 2020November 9th, 2020News

In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping pharmaceutical companies understand the biological mechanisms behind some of their most successful medicines, as well as how the company is currently developing a bold pipeline of drugs aimed at some of the most deadly forms of cancer.